Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

2022 ◽  
Vol 162 ◽  
pp. 138-147
Author(s):  
Morgane Stouvenot ◽  
Aurélia Meurisse ◽  
Angélique Saint ◽  
Bruno Buecher ◽  
Thierry André ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Pooled Analysis ◽  
Squamous Cell Carcinomas ◽  
Line Treatment ◽  
Second Line

scholarly journals Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal

2019 ◽  
Vol 8 (16) ◽  
pp. 6853-6859 ◽  
Author(s):  
Angélique Saint ◽  
Ludovic Evesque ◽  
Alexander T. Falk ◽  
Gérard Cavaglione ◽  
Lucile Montagne ◽  
...  
Keyword(s):  
Anal Canal ◽  
Squamous Cell ◽  
Squamous Cell Carcinomas ◽  
Line Treatment ◽  
Second Line

659 AN SINGLE-ARM OPEN-LABEL PHASE II STUDY OF CAMRELIZUMAB PLUS APATINIB AS SECOND-LINE TREATMENT FOR ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
Feng Wang ◽  
Qingxia Fan ◽  
Junsheng Wang ◽  
Tao Wu ◽  
Yonggui Hong ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Objective Response ◽  
Phase Iii ◽  
Line Treatment ◽  
Second Line

Abstract   Esophageal squamous cell carcinoma (ESCC) as a common malignancy is prevalent in East Asia and in eastern and southern Africa. Although pembrolizumab, nivolumab and camrelizumab are respectively recommended as second-line treatment for advanced ESCC due to improved overall survival (OS), objective response rate (ORR) was modest. New effective treatments are needed. Hence, the study of camrelizumab plus apatinib (VEGFR2 inhibitor) as second-line treatment for advanced ESCC was performed. Methods This ongoing phase II trial (NCT03736863) in six sites in China enrolled pts aged 18-75 with unresectable locally advanced, locally recurrent, or metastatic ESCC that progressed or were intolerant after first-line chemotherapy, and an ECOG performance status of 0-1. Pts received 200 mg camrelizumab intravenously every 2 weeks and apatinib 250 mg orally once per day in 4-week cycles until disease progression, unacceptable adverse events (AEs) or withdrawal of consent. The primary endpoint was investigator-assessed ORR. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS) and OS. Results At data cutoff (Feb 28, 2021), 52 pts were enrolled, including 42 males and 50 with distant metastases, with the median age of 62 years. In the evaluable population of 39 pts, ORR without confirmation was 43.59% and DCR was 94.87%. The median duration of response was 6.9 months (95% CI 4.57–9.23). The median PFS was 6.8 month (95% CI 2.66–10.94). The 12-month overall survival was 52.2%. A total of 80.8% of pts had treatment-related AEs (TRAEs) with 46.2% of grade ≥ 3 TRAEs. The safety profile of camrelizumab and apatinib was consistent with other anti–PD-1 antibodies and angiogenesis inhibitors. Conclusion This is the first study that evaluates the combination anti–PD-1 antibody and anti-angiogenesis inhibitor as a second-line therapy for advanced ESCC. Camrelizumab plus apatinib showed encouraging clinical efficacy and acceptable safety. Further phase III randomized trials are warranted.

Amrubicin (AMR) and cardiotoxicity in second-line treatment of small cell lung cancer (SCLC): A pooled analysis of left ventricular ejection fraction (LVEF) in two phase II trials

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19019-e19019
Author(s):  
D. R. Spigel ◽  
C. Shah ◽  
P. Lorigan ◽  
R. McNally ◽  
M. Renschler ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pooled Analysis ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Line Treatment ◽  
Second Line ◽  
Phase Ii Trials ◽  
Two Phase ◽  
Ventricular Ejection Fraction ◽  
Study Results

e19019 Background: Amrubicin (AMR) is a third-generation synthetic anthracycline and a potent topoisomerase II inhibitor approved in Japan for the treatment of lung cancer. In Japanese pre and postmarking studies, AMR treatment was not associated with cardiotoxicity. The purpose of this analysis was to determine if AMR treatment of Western patients (pts) is associated with anthracycline-induced cardiomyopathy. Methods: To evaluate risk of cardiomyopathy, LVEF was measured by echocardiogram or by multiple gated acquisition (MUGA) scan and pooled from pts enrolled in 2 trials of IV AMR, 40 mg/m2/day x 3 days q 21 days for second-line treatment of sensitive or refractory SCLC. Pts with measurable disease, ECOG PS 0–2, LVEF ≥50%, and prior platinum-based treatment were assessed at baseline (BL), cycles 3, 6, then every 2 cycles, and end of treatment. Pts were to be assessed by the same method (ECHO or MUGA) throughout the study. Pts with a persistent ≥20% decrease in LVEF during treatment were to be removed from the study. Results: 112 patients were treated (sensitive n=43, median 6 cycles; refractory, n=69, median 5 cycles) and had at least 1 LVEF assessment. Median age was 63 years and median BL LVEF was 60%. Changes in LVEF from baseline were minimal ( Table ) and similar across cumulative dosing groups including 15 pts who received a cumulative dose of >1,000 mg/m2 AMR. Two refractory pts (1.8%) experienced drops in LVEF >20%. One had BL LVEF of 85%, then 60% at cycle 3, and 70% subsequently with ongoing therapy. The second, with a history of cardiomegaly, had LVEF of 55% at BL, cycle 3, and 5 by ECHO, and 29% at the time of progression after cycle 9 (cumulative AMR dose 840 mg/m2) by MUGA. The patient died due to progressive disease with no evidence of CHF. Conclusions: In this pooled analysis of SCLC pts, LVEF remained stable even in pts with cumulative AMR dosing >1,000 mg/m2. AMR for second-line treatment of SCLC does not appear to cause anthracycline-related cardiomyopathy. [Table: see text] [Table: see text]

scholarly journals Apatinib plus S-1 as second-line or later line treatment for advanced squamous cell lung carcinoma

2018 ◽  
Vol 29 ◽  
pp. ix154-ix155
Author(s):  
Q. Shi ◽  
L. Xia ◽  
J. Zhou ◽  
Z. Wang ◽  
L. Sheng ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Lung Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Squamous Cell Lung Carcinoma ◽  
Cell Lung Carcinoma

scholarly journals Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment

2020 ◽  
Vol 2020 ◽  
pp. 1-4 ◽  
Author(s):  
Giandomenico Roviello ◽  
Andrea Casadei-Gardini ◽  
Stefania Nobili ◽  
Enrico Mini ◽  
Sara Fancelli
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Novel Agents ◽  
Line Treatment ◽  
Second Line ◽  
Novel Drugs ◽  
Phase Iii Trials ◽  
Male Patients ◽  
Extrahepatic Metastases

Background. Second line of treatment of hepatocellular carcinoma (HCC) has notably changed in recent years as three novel drugs with a different mechanism of action have demonstrated to improve survival compared to placebo; thus, there is a need to better define the profile of optimal candidates to second-line treatment with these drugs in order to maximize clinical benefit. Materials and Methods. We performed a pooled analysis from the subgroup analysis of all published phase III trials for approved targeted therapy in the second line of treatment for HCC, with the aim to discover possible clinical-pathological predictive factors. Results. Four studies were included in the analysis for a total of 2137 cases whose results supported the use of these novel agents in male patients with ECOG: 0, extrahepatic metastases, and HBV infection. Conclusions. Future studies are awaited to define best candidates for novel agents approved in the second line of treatment for HCC.

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis

2017 ◽  
Vol 44 (2) ◽  
pp. 114-128 ◽  
Author(s):  
Ralph Chebib ◽  
Loic Verlingue ◽  
Nathalie Cozic ◽  
Matthieu Faron ◽  
Pascal Burtin ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Metastatic Colorectal Cancer ◽  
Pooled Analysis ◽  
Line Treatment ◽  
Second Line ◽  
Angiogenesis Inhibition
Sign in / Sign up

Export Citation Format

Share Document